Close



Mar 21, 2024 07:00AM
Mar 20, 2024 07:00AM
Mar 20, 2024 07:00AM
Feb 1, 2024 04:30PM
Feb 1, 2024 04:30PM
Jan 8, 2024 07:02AM
Jan 8, 2024 07:00AM Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
Nov 9, 2023 07:00AM
Nov 6, 2023 07:00AM
Nov 6, 2023 07:00AM
Oct 2, 2023 07:07AM
Oct 2, 2023 07:00AM
Aug 10, 2023 07:00AM
May 16, 2023 07:01AM Cabaletta Bio (CABA) Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
May 16, 2023 07:00AM
May 15, 2023 09:10AM
May 15, 2023 09:08AM
May 11, 2023 07:00AM
May 1, 2023 07:00AM
May 1, 2023 07:00AM
May 1, 2023 07:00AM Cabaletta Bio Receives FDA Fast Track Designation for CABA-201
Mar 31, 2023 07:00AM
Mar 31, 2023 07:00AM
Mar 31, 2023 07:00AM
Mar 16, 2023 07:00AM
Mar 16, 2023 07:00AM
Dec 8, 2022 07:02AM
Dec 8, 2022 07:00AM Cabaletta Bio Announces $35 Million Offering
Dec 8, 2022 07:00AM
Nov 10, 2022 07:00AM
Nov 10, 2022 07:00AM
Oct 11, 2022 07:04AM
Oct 11, 2022 07:00AM
Oct 11, 2022 07:00AM
Oct 11, 2022 07:00AM IASO Biotherapeutics and Cabaletta Bio Announce Exclusive Worldwide License Agreement for Clinically Validated CD19 Binder
Aug 11, 2022 07:00AM
Aug 11, 2022 07:00AM
May 18, 2022 07:02AM
May 18, 2022 07:00AM
May 18, 2022 07:00AM
May 12, 2022 07:00AM
May 12, 2022 07:00AM Cabaletta Bio Reports First Quarter 2022 Financial Results and Provides Business Update
Mar 17, 2022 07:02AM
Mar 17, 2022 07:00AM
Mar 17, 2022 07:00AM
Mar 1, 2022 08:02AM
Mar 1, 2022 08:00AM
Mar 1, 2022 08:00AM
Jan 11, 2022 08:00AM Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer
Jan 11, 2022 08:00AM

251,865 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All